This information is intended for healthcare professionals based in Belgium and Luxembourg.
If you are not a healthcare professional, click here

Opdivo_Yervoy_Logo Opdivo_Yervoy_Logo Opdivo_Logo Opdivo_Chemotherapy_Logo
Neoadjuvant NSCLC Metastatic NSCLC Mesothelioma
Neoadjuvant NSCLC Metastatic NSCLC Mesothelioma
Renal Cell Carcinoma Urothelial cancer
Renal Cell Carcinoma Urothelial cancer
Advanced MelanomaAdjuvant Melanoma
Adjuvant esophageal (EC or GEJC) 1L adenocarcinoma upper GI 1L or 2L esophageal squamous cell carcinoma (ESCC)
Head & Neck
Hodgkin Lymphoma

Hodgkin Lymphoma

THE FIRST IMMUNOTHERAPY IN CHL

View indication details

  • OPDIVO as monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin.
Product information

Dosing scheme
OPDIVO in cHL

Practical user guide
based on OPDIVO SmPC

Patient & nurse materials

Patient brochure
with practical information
on immunotherapy

www.immunooncology.be

An educational website
on immunotherapy for your
nurses and your patients

Patient alert card
OPDIVO

Useful links

ImmunoScience Academy
An educational multi-disciplinary platform on immunology and immunotherapy

BSMO immunomanager Comprehensive recommendations
on the diagnostic algorithm and treatment of different types of irAE

Belgian Multidisciplinary Immunotoxicity Board (BITOX) Submit your case/questions
about irAEs

BSP poster
 PD-L1 testing
accross tumor indications

cHL, classical hodgkin lymphoma; irAE(s), immune-related adverse event(s)

You may contact our EU Data Protection Officer at EUDPO@BMS.com to exercise any data privacy rights that you may have, as well as to raise any concerns or questions in relation to the handling of your personal data by Bristol-Myers Squibb Company.